GlassScriptPhysician profile
Hilda Raisch
NPI 1376805713
$5,988.38
in general payments reported to CMS, 2019-2025
44 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.15 · 2022: $2,077 · 2023: $1,792 · 2024: $1,855 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,820.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,412.20 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $701.48 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $403.83 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $344.00 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $326.66 | 2022 | |
| Amgen INC. | $250.59 | 2022-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $227.68 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.31 | 2022-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.76 | 2023-2025 | Xifaxan, Trulance |
| Optinose US, INC. | $170.58 | 2022-2024 | |
| Glaxosmithkline, LLC. | $152.39 | 2022-2024 | Arexvy, Shingrix, Bexsero |
| Merck Sharp & Dohme LLC | $145.50 | 2022-2024 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $135.35 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $135.03 | 2023-2024 | Xarelto |
| Astellas Pharma US INC | $127.13 | 2023-2024 | Veozah |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $97.81 | 2022-2023 | |
| Lundbeck LLC | $97.73 | 2022-2024 | Vyepti |
| Exact Sciences Corporation | $85.70 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $73.81 | 2022-2024 | Rexulti |
| Amarin Pharma, INC. | $59.26 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $53.79 | 2023-2024 | Quviviq |
| Biogen, INC. | $52.35 | 2022 | |
| Dynavax Technologies Corporation | $51.62 | 2022-2024 | Heplisav-B |
| Axsome Therapeutics, INC. | $48.20 | 2023-2024 | Sunosi |
| Jazz Pharmaceuticals INC. | $38.48 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $37.45 | 2024 | Hetlioz, Fanapt |
| Corcept Therapeutics | $37.23 | 2024 | Korlym |
| Azurity Pharmaceuticals, INC. | $31.62 | 2023 | Horizant |
| Xeris Pharmaceuticals, INC. | $29.00 | 2021-2022 | |
| Seqirus USA INC | $28.96 | 2024 | Flucelvax, Fluad |
| Eisai INC. | $21.90 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $20.88 | 2021 | |
| Gilead Sciences, INC. | $20.08 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.96 | 2022 | |
| Corium, LLC | $19.63 | 2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.44 | 2025 | Caplyta |
| Organon LLC | $18.23 | 2023 | Nexplanon |
| Tris Pharma INC | $16.25 | 2022 | |
| Lucid Diagnostics INC. | $16.15 | 2022 | |
| Medtronic, INC. | $15.97 | 2024 | Closurefast |
| Nabriva Therapeutics, Plc | $14.92 | 2022 | |
| Tactile Systems Technology INC | $14.91 | 2023 | Flexitouch Plus, Entre Plus |
| Currax Pharmaceuticals LLC | $13.64 | 2023 | Onzetra Xsail, Contrave |
| Hikma Pharmaceuticals USA | $12.92 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hilda Raisch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.